Gene Editing Market by Product & Service (Reagents, Consumables, Systems, Software), Technology (CRISPR, TALEN, ZFN, Antisense), Application (Cell Line Engineering, Genetic Engineering, Drug Discovery), End User (Pharma, Biotech) – Global Forecast to 2028
Updated on : Aug 22, 2024
The global gene editing market in terms of revenue was estimated to be worth $5.3 billion in 2023 and is poised to reach $10.6 billion by 2028, growing at a CAGR of 15.0% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The key driving factors of the market include rising government funding and the number of genomics projects, growing applications of genomics, and introduction of CRISPR-Cas9. Whereas Extensive use of genome editing in personalized medicine and expanding pipeline for gene therapy are anticipated to create lucrative opportunities for players operational in market. However, off-target effects of CRISPR technology are expected to restrain market growth. Presently, high equipment costs pose a challenge to the professionals operating in this market. Introduction of affordable products/equipment is expected to mitigate the impact of this challenge.
Gene Editing Market Size, Dynamics & Ecosystem
To know about the assumptions considered for the study, Request for Free Sample Report
Gene Editing Market Dynamics
DRIVER: Growing applications of genomics
Future trends in genomic engineering include its use in marine engineering for applications such as developing nutraceuticals from algae. Forensic sciences and personalized medicine are some of the other upcoming application areas. NGS can be used for DNA barcoding to identify fish larvae and eggs, along with the complete description of fish communities while assessing fish populations. Genomics is increasingly being used in food quality and safety testing. Genome editing technologies are vital in drug discovery and diagnosing and treating human genetic disorders. Genome editing is also used in NGS, DNA analysis & profiling, and plant and animal genetic engineering. Thus, with the growing application areas of genomics, the demand for genome editing technologies is expected to increase during the forecast period.
RESTRAINT: Off-target effects of CRISPR technology
The off-target effects of CRISPR technology pose a significant restraint in gene editing. While CRISPR-Cas9 offers remarkable precision in targeting specific genes, it can also result in unintended modifications at sites other than the intended target. This off-target activity can lead to potential risks and challenges in applying CRISPR technology. Ensuring accurate targeting is crucial to minimize the risk of unintended modifications and potential adverse effects. Researchers are refining CRISPR techniques and developing strategies to improve specificity and reduce off-target effects. Advancements such as high-fidelity Cas9 variants, improved guide RNA design, and bioinformatics tools have shown promise in mitigating off-target activity.
OPPORTUNITY: Expanding pipeline for gene therapy
The expanding pipeline for gene therapy in the gene editing industry presents significant opportunities for advancements in treating genetic disorders and other diseases. Gene therapy involves the delivery of therapeutic genes or gene editing tools into the patient’s cells to correct genetic mutations, restore normal gene function, or introduce therapeutic genes for targeted treatment. The growing number of gene therapy candidates in the development pipeline highlights the potential for transformative breakthroughs in personalized medicine and the treatment of previously incurable diseases.
CHALLENGE: High equipment costs
The costs associated with gene editing equipment can be substantial. For instance, gene editing technologies like CRISPR-Cas9 require specialized laboratory equipment, including DNA sequencers, thermal cyclers, electroporation devices, and fluorescence microscopes. These instruments can have high price tags, ranging from thousands to millions of dollars. In addition to equipment costs, procuring quality reagents, such as nucleases, guide RNAs, and donor templates, can contribute to the overall expenses.
Gene Editing Market Ecosystem
R&D is the initial stage in the value chain of the market. Extensive R&D is required to develop these products. R&D activities are divided into in-house and outsourced tasks. In-house tasks focus on critical activities that deal with fundamental analysis and the electronic interpretation of testing parameters. Prominent companies providing gene editing products & services, SMEs, distributors, and end customers (pharmaceutical & biotechnology companies, academic & research institutions, and diagnostic companies) are the key stakeholders in the supply chain of the gene editing industry. Investors/funders are the major influencers in the market.
The prominent players in the global gene editing market are Merck KGaA (Germany), Thermo Fisher Scientific, Inc. (US), GenScript (China), Agilent Technologies (US), PerkinElmer (US), Lonza (Switzerland), Tecan Life Sciences (Switzerland), Sangamo Therapeutics (US), Editas Medicine (US), CRISPR Therapeutics AG (Switzerland), Precision Biosciences (US), Cellectis S.A. (France), Intellia Therapeutics (US), Bluebird Bio, Inc. (US), Regeneron Pharmaceuticals (US), AMSBIO (England), Creative Biogene (US), Synthego Corporation (US), and Beam Therapeutics Inc. (US). Others include Caribou Biosciences, Inc. (US), OriGene Technologies (US), New England Biolabs (US), Inscripta (US), and Mammoth Biosciences (US).
Gene Editing Market Segmentation & Geographical Spread
To know about the assumptions considered for the study, download the pdf brochure
Based on product & service, reagents & consumables segment accounted for the largest share of the gene editing industry in 2022
Based on product & service, the gene editing market is segmented into reagents & consumables, software & systems, and services. The reagents & consumables segment accounted for the largest share in 2022. Reagents and consumables include various products, such as library preparation, purification, and target enrichment kits; plates; chips; tube strips; foil seals; plate holders; and slide holders. The growing applications of genomics in various fields are expected to boost the consumables market. Advancements in library preparation technologies have also enabled the use of NGS in epigenetics and transcriptomics. These kits are used in sequencing applications, such as whole-genome and targeted DNA sequencing.
Based on technology, CRISPR segment accounted for the largest share of the gene editing industry in 2022
Based on technology, the gene editing market is segmented into TALEN, CRISPR, antisense, ZFN, and other technologies. The CRISPR segment dominated the market with the highest share of in 2022. CRISPR-Clustered Regularly Interspaced Short Palindromic Repeats has emerged as a pivotal tool for gene editing as an alternative to traditional genetic modification techniques. Cas9 enzymes differentiate CRISPR from other forms of genetic modification. CRISPR edits and rearranges genes by cutting out the damaged or unwanted part of the DNA, allowing the remaining DNA to be rearranged in a new way.
The North America region is projected to contribute the largest share for the gene editing industry.
The global gene editing market is segmented into five major regions—North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is the largest regional market for gene editing. US has emerged as the key revenue contributor to this region. The gene editing space has attracted significant investments and funding from venture capitalists, government agencies, and private entities in the US. This funding has fueled R&D efforts and the translation of gene editing technologies into commercial applications. The availability of capital has facilitated the growth of gene editing companies and the advancement of therapeutic interventions.
The global gene editing market is a fragmented market, with Merck KGaA (Germany), Thermo Fisher Scientific, Inc. (US), GenScript (China) emerging as the top 3 players of the global market. Players such as Agilent Technologies (US), PerkinElmer (US), Lonza (Switzerland), Tecan Life Sciences (Switzerland), Sangamo Therapeutics (US), Editas Medicine (US), CRISPR Therapeutics AG (Switzerland), Precision Biosciences (US), Cellectis S.A. (France), Intellia Therapeutics (US), Bluebird Bio, Inc. (US), Regeneron Pharmaceuticals (US), AMSBIO (England), Creative Biogene (US), Synthego Corporation (US), and Beam Therapeutics Inc. (US). Others include Caribou Biosciences, Inc. (US), OriGene Technologies (US), New England Biolabs (US), Inscripta (US), and Mammoth Biosciences (US) are some of the prominent players in the market.
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
|
Report Metric |
Details |
|
Market Size Available for Years |
2021–2028 |
|
Base Year Considered |
2022 |
|
Forecast Period |
2023–2028 |
|
Forecast Units |
Value (USD Million/Billion) |
|
Segments Covered |
Product & Service, Technology, Application, End User, And Region |
|
Geographies Covered |
North America, Europe, Asia Pacific, Latin America and MEA |
|
Companies Covered |
Merck KGaA (Germany), Thermo Fisher Scientific, Inc. (US), GenScript (China), Agilent Technologies (US), PerkinElmer (US), Lonza (Switzerland), Tecan Life Sciences (Switzerland), Sangamo Therapeutics (US), Editas Medicine (US), CRISPR Therapeutics AG (Switzerland), Precision Biosciences (US), Cellectis S.A. (France), Intellia Therapeutics (US), Bluebird Bio, Inc. (US), Regeneron Pharmaceuticals (US), AMSBIO (England), Creative Biogene (US), Synthego Corporation (US), and Beam Therapeutics Inc. (US), Caribou Biosciences, Inc. (US), OriGene Technologies (US), New England Biolabs (US), Inscripta (US), and Mammoth Biosciences (US). |
This research report categorizes the gene editing market into the following segments:
Product & Service
- Reagents & Consumables
- Software & Systems
- Services
Technology
- CRISPR
- TALEN
- ZFN
- ANTISENSE
- Other technologies
Application
- Cell Line Engineering
- Genetic Engineering
- Drug Discovery & Development
- Other Applications
End User
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Other End Users
Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Spain
- Italy
- RoE
-
Asia Pacific
- China
- India
- Japan
- RoAPAC
-
Latin America
- Brazil
- RoLATAM
- Middle East & Africa
Recent Developments of Gene Editing Industry
- In February 2023, GenScript (China) announced the expansion of its Singapore facility to provide a premium gene synthesis service. This marks a significant expansion of the company’s advanced gene-synthesis capability and enables GenScript to provide the service levels required for novel vaccine and therapeutics development in life sciences.
- In November 2022, Thermo Fisher Scientific (US) announced the launch of Gibco CTS AAV-MAX Helper-Free AAV Production System, an all-in-one solution suitable for commercial and clinical applications associated with AAV-based gene therapies.
- In June 2022, Lonza (Switzerland) and Adva entered into a license agreement that will allow Adva to develop innovative solutions for the cell and gene therapies industry.
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the global gene editing market?
The global gene editing market boasts a total revenue value of $10.6 billion by 2028.
What is the estimated growth rate (CAGR) of the global gene editing market?
The global gene editing market has an estimated compound annual growth rate (CAGR) of 15.0% and a revenue size in the region of $5.3 billion in 2023.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
This study involved four major activities in estimating the current size of the gene editing market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the gene editing market. The secondary sources used for this study include publications from government sources such as International Chromosome and Genome Society (ICGS), the National Human Genome Research Institute (NHGRI), the Asia Pacific Society of Human Genetics (APSHG), the Genetics Society of America (GSA), the European Society of Human Genetics (ESHG), Centers for Common Disease Genomics (CDDG), Centre for Cellular & Molecular Biology (CCMB) (India), and the Department of Biotechnology (DBT) (India), Annual Reports, SEC Fillings, Press Releases, Investor Presentation, Expert Interviews, and MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the gene editing market. These methods were also used extensively to estimate the size of various segments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and markets have been identified through extensive secondary research
- The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Data Triangulation
After arriving at the overall market size—using the market size estimation processes—the market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics of each market segments, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the gene editing industry.
Market Definition
Gene editing or genome engineering is the insertion, deletion, or replacement of DNA at a specific site in the genome of an organism or cell. It is usually achieved in the lab using genome-editing tools, such as CRISPR, TALEN, and ZFN. This emerging and rapidly evolving field enables the efficient and directed modification of cell lines and genomes of animals and plants.
Key Stakeholders
- Genome editing/genome engineering product manufacturers
- Suppliers and distributors of genomic instruments/systems and consumables
- Contract manufacturing organizations
- Pharmaceutical and biotechnology companies
- Diagnostic centers and medical colleges
- Contract research organizations
- Government associations and research institutes
- Healthcare associations/institutes
- Regulatory authorities
- Business research firms
Report Objectives
- To define, describe, and forecast the gene editing market based on technology, product & service, application, end user, and region
- To provide detailed information about the drivers, restraints, opportunities, and challenges influencing the market growth
- To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall gene editing market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of market segments in North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), and the Middle East & Africa (MEA)
- To profile the key players and comprehensively analyze their core competencies2 in terms of key developments, product portfolios, and financials
- To track and analyze competitive developments, such as product/service launches, partnerships, collaborations, agreements, and acquisitions, in the gene editing market
Micromarkets are the further segments and subsegments of the gene editing market.
Core competencies of companies are captured in terms of the key developments, market shares, and key strategies adopted to sustain their positions in the market.
Available Customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
- Company Information: Detailed analysis and profiling of additional market players (up to five)
- Geographic Analysis: Further breakdown of the RoE gene editing market, by country. Further breakdown of the RoAPAC gene editing market, by country. Further breakdown of the RoLATAM and MEA gene editing markets, by country.
Generating Response ...
Growth opportunities and latent adjacency in Gene Editing Market